We are known for the quality of our in-house developed and validated state-of-the-art single-domain antibodies (sdAbs). Benefit from our experience and get in touch with our experienced scientists to realize your sdAb project.
BioNTech to Evaluate NanoTag’s Target Labeling System in Different Therapeutic Areas
BioNTech gains rights to exclusively evaluate NanoTag’s target labeling system “ALFA” across indications in oncology and infectious diseases in both a preclinical and clinical setting. The high specificity of the ALFA tag-antibody binding has the potential for different use cases that BioNTech intends to evaluate, including drug delivery.
Browse our Shop to discover new sdAb developments and explore our thoroughly-validated products. NanoTag's sdAb-based solutions are tailored to make your research and development faster, more precise, and reproducible.
We provide highly customized services for your project. From protein production, advanced modifications of sdAbs, functional validations, and the discovery of specific sdAbs tailored to your needs.
NanoTag's discovery program to generate and characterize novel single-domain antibodies directed against specific targets with high potential in therapeutic applications.
Superior affinity reagents for R&D and pre-clinical studies
Our goal is to provide high-quality recombinant affinity molecules supporting therapeutic and diagnostic industries and to create superior, sustainable, and more reproducible reagents for biomedical research.